Novartis Pharmaceuticals collaborates with Qualcomm in digital innovation with the Breezhaler(TM) inhaler device to treat COPD
- Details
- Category: Novartis
Novartis announced today a collaboration with Qualcomm Incorporated through its subsidiary, Qualcomm Life, Inc., in digital innovation with the Breezhaler(TM) inhaler device to treat COPD. Under this collaboration, Qualcomm Life will provide the technology solution for the connectivity of the next generation of the Breezhaler(TM) inhaler,
Merck KGaA, Darmstadt, Germany, Pfizer and Syndax announce collaboration to evaluate combination of Avelumab and Entinostat in ovarian cancer
- Details
- Category: Pfizer
Merck KGaA, Darmstadt, Germany, Pfizer and Syndax Pharmaceuticals, Inc. announced today that they have entered into a collaboration agreement to evaluate avelumab*, an investigational fully human anti-PD-L1 IgG1 monoclonal antibody, in combination with Syndax's entinostat, an investigational oral small molecule that targets immune regulatory cells (myeloid-derived suppressor cells and regulatory T-cells), in patients with heavily pre-treated, recurrent ovarian cancer.
Boehringer Ingelheim 3rd-generation EGFR TKI, BI 1482694, receives FDA Breakthrough Therapy Designation in lung cancer
- Details
- Category: Boehringer Ingelheim
Boehringer Ingelheim today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for its novel, 3rd-generation, epidermal growth factor receptor (EGFR) mutation-specific tyrosine kinase inhibitor (TKI), BI 1482694* (HM61713**).
Bayer and CRISPR Therapeutics AG join forces to discover, develop and commercialize potential cures for serious genetic diseases
- Details
- Category: Bayer
Bayer and CRISPR Therapeutics have entered into an agreement to create a joint venture (JV) to discover, develop and commercialize new breakthrough therapeutics to cure blood disorders, blindness, and congenital heart disease.
Bristol-Myers Squibb to sell its HIV R&D portfolio to ViiV Healthcare
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE:BMY) today announced that it has entered into two individual agreements with ViiV Healthcare, a global HIV company, to divest its pipeline of investigational HIV medicines consisting of a number of programs at different stages of discovery, preclinical and clinical development.
AstraZeneca enhances long-term growth through oncology investment in Acerta Pharma
- Details
- Category: AstraZeneca
AstraZeneca has entered into an agreement to invest in a majority equity stake in Acerta Pharma, a privately-owned biopharmaceutical company based in the Netherlands and US. The transaction provides AstraZeneca with a potential best-in-class irreversible oral Bruton's tyrosine kinase (BTK) inhibitor, acalabrutinib (ACP-196), currently in Phase III development for B-cell blood cancers and in Phase I/II clinical trials in multiple solid tumours.
Takeda announces sale of respiratory portfolio to AstraZeneca
- Details
- Category: Takeda
Takeda Pharmaceutical Company Limited (TOKYO:4502) has entered into a definitive agreement to sell its respiratory portfolio to AstraZeneca. In 2014 Takeda defined four therapeutic areas of focus: Gastroenterology, Oncology, Central Nervous System, and Cardiovascular and Metabolic.
More Pharma News ...
- AstraZeneca to strengthen therapy area franchise through acquisition of Takeda's respiratory business
- Amgen reacquires all product rights to Prolia® (denosumab), XGEVA® (denosumab) and Vectibix® (panitumumab) from GSK in 48 countries
- Bristol-Myers Squibb and UCLA enter into a collaboration agreement
- Abbott and UC San Francisco discover new virus is linked to hepatitis C
- AstraZeneca to harness power of the Secretome and develop next-generation biologics in collaboration with new Wallenberg Centre for Protein Research
- Novo Nordisk and IBM partner to build diabetes care solutions on the Watson Health Cloud
- Shire partners with CrowdMed to offer US employees an innovative digital crowdsourcing diagnostic service